Tissue-specific interactome destabilization drives phenotype divergence in Mendelian neurological diseases

Target: %s Composite Score: 0.000 Price: $0.50 Citation Quality: Pending Mendelian neurological diseases (neurodegeneration) Status: proposed
☰ Compare⚛ Collideinteract with this hypothesis
⚠ No Target Gene⚠ Low Validation Senate Quality Gates →
Evidence Strength Pending (0%)
3
Citations
1
Debates
3
Supporting
0
Opposing
Quality Report Card click to collapse
F
Composite: 0.000
Top 50% of 1512 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
F Mech. Plausibility 15% 0.00 Top 50%
B Evidence Strength 15% 0.68 Top 30%
B+ Novelty 12% 0.72 Top 40%
B+ Feasibility 12% 0.75 Top 26%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
3 supporting | 0 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 0.95

From Analysis:

What molecular mechanisms drive tissue-specific phenotypes in Mendelian neurological diseases?

The abstract identifies tissue-specific networks that may underlie Mendelian disease phenotypes but doesn't explain the mechanistic basis for why the same genetic variant causes different phenotypes across tissues. Understanding these mechanisms is crucial for developing tissue-targeted therapies for neurogenetic disorders. Gap type: unexplained_observation Source paper: A reference map of the human binary protein interactome. (2020, Nature, PMID:32296183)

→ View full analysis & debate transcript

Description

Disease-causing mutations in shared genes produce tissue-specific phenotypes because the mutant protein exhibits differential incorporation into multi-protein complexes based on tissue-specific expression of complex subunits and post-translational modifications. In affected neuronal tissues, the mutation preferentially disrupts complexes essential for synaptic function, axonal transport, or mitochondrial dynamics, while unaffected tissues compensate through alternative complex compositions or protective PTM states.

...

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.00 (15%) Evidence 0.68 (15%) Novelty 0.72 (12%) Feasibility 0.75 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.000 composite
3 citations 3 with PMID 3 medium Validation: 0% 3 supporting / 0 opposing
For (3)
3
No opposing evidence
(0) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
MECH 0CLIN 0GENE 3EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Network propagation of rare variants in Alzheimer&…SupportingGENEPLoS Comput Bio… MEDIUM2021-PMID:33411734-
Understanding multicellular function and disease w…SupportingGENENat Genet MEDIUM2015-PMID:25915600-
Genome-wide meta-analysis, fine-mapping and integr…SupportingGENENat Genet MEDIUM2021-PMID:33589840-
Legacy Card View — expandable citation cards

Supporting Evidence 3

Network propagation of rare variants in Alzheimer's disease reveals tissue-specific hub genes and communities. MEDIUM
PLoS Comput Biol · 2021 · PMID:33411734
Understanding multicellular function and disease with human tissue-specific networks. MEDIUM
Nat Genet · 2015 · PMID:25915600
Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk … MEDIUM
Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes.
Nat Genet · 2021 · PMID:33589840

Opposing Evidence 0

No evidence recorded
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 6 rounds | 2026-04-10 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the identified knowledge gap regarding tissue-specific manifestations of Mendelian diseases, I'll generate novel therapeutic hypotheses that address why the same genetic variant causes different phenotypes across tissues:

Hypothesis 1: Tissue-Specific Protein Interaction Buffer Modulation

Description: Different tissues have varying "buffer capacities" of redundant protein interactions that can compensate for a mutated protein. Therapeutic intervention could involve enhancing these compensatory networks in vulnerable tissues through targeted upregulation of alternative interact

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Now I have sufficient background. Let me critically evaluate each hypothesis:

Critical Evaluation of Therapeutic Hypotheses

Hypothesis 1: Tissue-Specific Protein Interaction Buffer Modulation

Major Weaknesses:

  • Oversimplified buffering concept: The hypothesis assumes linear compensatory relationships, but protein networks exhibit non-linear dynamics with threshold effects and cooperative binding. The Luck et al. (2020) interactome map captures binary interactions but misses the dynamic, concentration-dependent nature of protein complexes.
  • Technical feasibility gap:
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Competitive landscape:

    • Reata Pharmaceuticals (bardoxolone) - experienced safety setbacks
    • Multiple biotech companies developing NRF2 modulators
    • Established safety concerns from terminated trials (NCT01351675)
    Cost/Timeline: $200-350M / 8-12 years Safety concerns: Moderate-High - bardoxolone showed cardiovascular risks

    VERDICT: FEASIBLE but with significant safety hurdles

    OVERALL FEASIBILITY RANKING

    1. METABOLIC MODULATION (Hypothesis 3) - HIGHEST FEASIBILITY

    • Advantages: Existing drugs, established safety, repurposing opportunity
    • Timeline: 6-10 ye

    Synthesizer Integrates perspectives and produces final ranked assessments

    Price History

    No price history recorded yet

    7d Trend
    Stable
    7d Momentum
    ▲ 0.0%
    Volatility
    Low
    0.0000
    Events (7d)
    0

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (3)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.0th percentile (760 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    3

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.050

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    Related Hypotheses

    No related hypotheses found

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (0 edges)

    No knowledge graph edges recorded

    Source Analysis

    What molecular mechanisms drive tissue-specific phenotypes in Mendelian neurological diseases?

    neurodegeneration | 2026-04-08 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)